This includes the cost of your provider visits, medication, supplies, and ongoing support.
The actual clinical evidence for resM specifically is still developing, with a randomized, placebo-controlled trial currently in progress at ClinicalTrials.gov
"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity: a randomised, double-blind, ascending dose phase 1 clinical trial." The Lancet 392.10160 (2018): 2180-2193
For those without access to Retatrutide, Tirzepatide remains an excellent choice that represents the current gold standard in approved treatments
Du, et al., 'The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity', Kidney Int